Elinzanetant is a once-daily oral drug that blocks two brain receptors instead of one, approved in the UK in July 2025 and by the FDA, as Lynkuet, in October 2025, with US availability from November 2025.
In trials it reduced hot flash frequency and significantly improved sleep disturbance and quality of life, with the extra receptor blockade thought to contribute the added sleep benefit. No head-to-head trial against fezolinetant exists, but an indirect comparison across pooled trial data suggested elinzanetant produced a somewhat larger reduction in flashes and the largest sleep improvement among the drugs compared.
No head-to-head trial between elinzanetant and fezolinetant exists, so any claim that one is simply better rests on indirect, cross-trial comparison, which is a weaker form of evidence than a direct comparative trial.
What the research shows, and which source each finding rests on
In the twin OASIS 1 and 2 phase 3 trials (n = 796 total), versus placebo at week 12, elinzanetant 120 mg reduced daily moderate-to-severe vasomotor symptom frequency by an additional 3.2 episodes in both trials (p < 0.001), and significantly improved sleep disturbance and menopause-related quality of life
OASIS 3, a 52-week trial (n = 628) with no minimum vasomotor symptom frequency required for entry, found week-12 change in daily moderate-to-severe symptoms of -5.4 versus -3.5 for placebo (difference -1.6, p < 0.001); no hepatotoxic effects, no endometrial hyperplasia, and no meaningful bone changes were seen, with treatment-related adverse events in 30.4 percent versus 14.6 percent, mostly somnolence, fatigue, and headache
First worldwide approval was by the UK MHRA on 8 July 2025; FDA approval as Lynkuet followed on 24 October 2025, as the first dual NK1/NK3 receptor antagonist for moderate-to-severe vasomotor symptoms, with US availability from November 2025
Where the real disagreement is
Each position is shown with its own sources. A position listed here is not necessarily the accepted view.
Indirect comparison suggests an edge, but it isn't proof
The authors of the 2025 pooled meta-analysis
The pooled numbers point toward elinzanetant having a somewhat larger placebo-adjusted effect and clearly the largest sleep benefit, but different trials enrolled women with different baseline flash frequencies, since OASIS 3 required no minimum unlike the fezolinetant trials, which can distort cross-trial comparisons.
What would settle it: A randomized head-to-head trial directly comparing elinzanetant and fezolinetant, ideally also against transdermal estradiol, with vasomotor symptom, sleep, and quality-of-life endpoints.
What is really going on here
- Does this trial population match me? OASIS 3 enrolled women without a minimum flash count and found a smaller absolute drug-placebo gap than the high-frequency trials, and effect sizes travel poorly across different baselines.
Questions for your doctor
- Is elinzanetant available and appropriate for me, especially if sleep disturbance is a major complaint?
- How does my hot flash frequency compare to what the trials studied, and does that affect what result I should expect?
- What are the most common side effects I should watch for, such as somnolence, fatigue, or headache?
- If I'm not a hormone therapy candidate, how does this compare with fezolinetant for my situation?
Questions with no answer yet
If the extra receptor this drug blocks, beyond the one an earlier drug targets, is what drives its larger sleep benefit, would adding that same receptor-blocking effect to the earlier drug produce a similar sleep improvement?
Not directly studied yetNo research does not mean it does not work, and it does not mean it works. It means nobody has tested it yet.
What is known: One expert discussion proposes that the added receptor activity could explain the larger sleep effect, matching the trial's own findings, but no study has directly tested whether that specific added mechanism, isolated from everything else different between the two drugs, is what accounts for the sleep difference.
What would test it: A mechanistic or dose-comparison study isolating the specific contribution of the added receptor blockade to the observed sleep benefit.
Since no head-to-head trial exists, is the apparently larger effect size seen in the indirect meta-analysis a true difference between the two drugs, or an artifact of the trials enrolling women with different baseline hot flash frequencies?
Not directly studied yetNo research does not mean it does not work, and it does not mean it works. It means nobody has tested it yet.
What is known: Different trials enrolled women with different baseline flash frequencies, since one trial required no minimum unlike the earlier trials, which can distort cross-trial comparisons. A randomized head-to-head trial is described as what would settle whether one drug truly has an edge.
What would test it: A randomized head-to-head trial directly comparing the two drugs, ideally also against transdermal estradiol.
Does this newer drug carry the same rare liver-injury signal as the earlier one, or is the apparent difference in year-one safety data simply because it has been on the market for far less time?
Not directly studied yetNo research does not mean it does not work, and it does not mean it works. It means nobody has tested it yet.
What is known: The newer drug's pivotal 52-week trial found no hepatotoxic effects, but it has been available for a much shorter period in the real world than the earlier drug, whose rare liver signal only appeared after wider postmarketing use.
What would test it: Continued postmarketing surveillance of the newer drug over a comparable time period to what revealed the earlier drug's rare signal.
Sources
- 1.Elinzanetant for the Treatment of Vasomotor Symptoms Associated With Menopause: OASIS 1 and 2 Randomized Clinical Trials.Pinkerton JV et al., JAMA 2024 · Comparative or small study
- 2.Elinzanetant for the Treatment of Vasomotor Symptoms Associated With Menopause: A Phase 3 Randomized Clinical Trial.Panay N et al., JAMA Intern Med 2025 · Randomised trial
- 3.Bayer press releases and Drugs.com approval history, 2025Review, opinion or mechanism
- 4.Fezolinetant and Elinzanetant Therapy for Menopausal Women Experiencing Vasomotor Symptoms: A Systematic Review and Meta-analysis.Menegaz de Almeida A et al., Obstet Gynecol 2025 · Systematic review or guideline
The letter grades the type of study behind a claim, not the answer itself.
This page is general information based on published research and public sources. It is not medical advice and not a personal assessment, and it does not replace a conversation with your doctor. Peritale is a wellness product, not a medical device, and is not intended to diagnose, treat, cure or prevent any disease. For any medical question, speak with a licensed clinician.
You are not imagining it
In about seven minutes on your phone, Peritale reads five signal systems and maps your symptoms, so you can see that what you feel is real, follow your hormonal transition over time, and walk into your doctor ready to ask for the care you deserve. Your first check is free, no credit card.
Start Free MappingRelated questions
- How long do hot flashes actually last?
- What actually causes a hot flash in my body?
- Are my hot flashes just uncomfortable, or could they be a warning sign about my heart or brain health?
- What is fezolinetant (Veozah) and is it safe to take for hot flashes?
- Are the new non-hormonal drugs (fezolinetant, elinzanetant) as good as hormone therapy for hot flashes?
- How do I know if a hot flash treatment actually works, versus me just wanting it to work?
- Back to topic: Hot flashes and their treatments